Stephanie Lheureux

610 University Ave
Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 181 publications

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Journal: JAMA oncology

Published: June 25, 2026

Immune checkpoint blockade sensitivity is linked to endogenous retroelement transcriptional changes in cancer.

Immune checkpoint blockade sensitivity is linked to endogenous retroelement transcriptional changes in cancer.

Journal: Cancer immunology research

Published: May 12, 2026

Immune profiling by bulk RNA-seq and multiplex immunofluorescence imaging across multiple cancer types.

Immune profiling by bulk RNA-seq and multiplex immunofluorescence imaging across multiple cancer types.

Journal: Frontiers in oncology

Published: May 09, 2026

Refractory ultra-high-risk Choriocarcinoma achieving complete response to intensive multi-agent and intrathecal chemotherapy and anti-PD-L1 therapy.

Refractory ultra-high-risk Choriocarcinoma achieving complete response to intensive multi-agent and intrathecal chemotherapy and anti-PD-L1 therapy.

Journal: Gynecologic oncology reports

Published: April 10, 2026

Rethinking ovarian cancer III: the past decade and future directions.

Rethinking ovarian cancer III: the past decade and future directions.

Journal: Nature reviews. Cancer

Published: February 23, 2026

Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay.

Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay.

Journal: International journal of molecular sciences

Published: February 14, 2026

Factors influencing care for patients with gynecologic malignancies from culturally and linguistically diverse backgrounds: a questionnaire study (iCALD-2).

Factors influencing care for patients with gynecologic malignancies from culturally and linguistically diverse backgrounds: a questionnaire study (iCALD-2).

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: November 20, 2025

Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report.

Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report.

Journal: Cancer research communications

Published: October 16, 2025

Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium.

Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium.

Journal: European journal of human genetics : EJHG

Published: September 30, 2025

CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).

CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).

Journal: Cancer treatment and research communications

Published: September 30, 2025

First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial.

First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 09, 2025

Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab.

Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab.

Journal: NPJ precision oncology

Published: August 11, 2025

Showing 1-12 of 181

Last Updated: 09/26/2026